Oppenheimer Reiterates Perform On Vertex Pharmaceuticals On The Back Of 3Q14 Earnings Release
In a research report issued to investors Wednesday, Oppenheimer analyst Yigal Nochomovitz reiterated a Perform rating on Vertex Pharmaceuticals (NASDAQ:VRTX), following the company’s third-quarter results, posting an adjusted EPS of ($0.37) that topped the consensus estimate of ($0.44). No price target was provided.
“We see 2015 as a transformative year for Vertex’s P&L with ~150% top-line growth and potential transition to profitability.”, Nochomovitz noted.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Yigal Nochomovitz has a total average return of 6.8% and a 50.0% success rate. Nochomovitz is ranked #1902 out of 3350 analysts.